ProKidney Investor Relations Material
Latest events
Status Update
ProKidney
Q1 2025
12 May, 2025
Q4 2024
17 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ProKidney Corp
Access all reports
ProKidney Corp is a clinical-stage biotechnology company focused on the development of cell therapy products for chronic kidney disease. Its lead candidate is based on autologous cell therapy aimed at preserving kidney function. The company is headquartered in Winston-Salem, North Carolina, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PROK
Country
🇺🇸 United States